Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD


ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from a Phase III study of SPN-812 in adults (P306) for the treatment of attention deficit hyperactivity disorder (ADHD).

See the original post:
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD

Related Posts